JPM26: Roche's rejuvenation strategy for the oncology and haematology portfolio [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
Key priorities outlined by Graham include maximising the on-market portfolio to sustain growth until 2028, delivering key launches to support momentum, and preparing wide entry into novel disease areas (Alzheimer's, obesity) via new molecular entities (NMEs) with a broad and diversified pipeline. The company is on track to achieve its 2025 financial goal, with YTD sales by September 2025 reaching CHF 35.6bn ($44.5 bn), CHF 18bn ($22.5bn) coming from its oncology and haematology portfolio. The currently marketed portfolio continues to grow and progress with 17 blockbuster drugs. In oncology/haematology, areas of strength are in breast cancer (Phesgo, Kadcyla, Perjeta, Itovebi), solid tumors (Tecentriq), diffuse large B-cell lymphoma (DLBCL) (Polivy, Columvi/Lunsumio), and haemophilia A (Hemlibra). Graham noted that Roche builds and accelerates its pipeline through partnering and acquisitions. For about 60% of Roche's R&D pipeline and total drug sales, the company has a partnership.
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Insider Sells $8 Million in Shares After 300% Stock Surge [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals (NASDAQ:OLMA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- How Bullish Analyst Coverage and New Capital Raise Could Impact Olema Pharmaceuticals (OLMA) Investors [Yahoo! Finance]Yahoo! Finance
- The banker, the brothers, the friends and their frauds [Investment Executive - News]Investment Executive - News
- Olema Pharmaceuticals (NASDAQ:OLMA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.MarketBeat
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 1/15/26 - Form 4
- 1/15/26 - Form 144
- 1/14/26 - Form 4
- OLMA's page on the SEC website